RAPT Therapeutics, Inc.
RAPTDelisted Mar 3, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001673772
RAPT Therapeutics, Inc. was delisted on Mar 3, 2026; its insiders filed their last Form 4 on Mar 5, 2026; 106 institutions reported holding it in 13F filings for Q4 2025, worth $1.02B in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 106
- Q4 2025, +42 vs. previous quarter
- 13F value
- $1.02B
- Reported value at the end of Q4 2025
- Superinvestors holding
- 0
- At the end of Q4 2025
Superinvestors holding RAPT, Q4 2025
No superinvestor reported holding RAPT at the end of Q4 2025.
Latest insider trades
Open-market purchases and sales by RAPT Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 8, 2024 (view filing) | Jan 5 | 3 days | Brockstedt Dirk G.CHIEF SCIENTIFIC OFFICER | SSale | −898 | $22.78 | −$20.5K | −3.1%27.8K after | |
| Dec 22, 2023 (view filing) | Dec 21 | 1 day | Ho WilliamChief Medical Officer | SSale | −2.50K | $21.68 | −$54.2K | −14.3%15.0K after | |
| Nov 29, 2023 (view filing) | Nov 28 | 1 day | Ho WilliamChief Medical Officer | SSale | −1.50K | $13.72 | −$20.6K | −7.9%17.5K after | |
| Oct 4, 2023 (view filing) | Oct 3 | 1 day | Ho WilliamChief Medical Officer | SSale | −2.50K | $15.77 | −$39.4K | −11.7%18.8K after | |
| Aug 22, 2023 (view filing) | Aug 18 | 4 days | Ho WilliamChief Medical Officer | SSale | −2.50K | $18.92 | −$47.3K | −10.5%21.3K after | |
| Apr 20, 2023 (view filing) | Apr 19 | 1 day | Ho WilliamChief Medical Officer | SSale | −5.00K | $18.88 | −$94.4K | −19.2%21.0K after | |
| Mar 15, 2023 (view filing) | Mar 14 | 1 day | Robbins WendyeDirector | PPurchase | +2.50K | $18.99 | +$47.5K | +20.2%14.9K after | 3 lots |
| Mar 15, 2023 (view filing) | Mar 14 | 1 day | Robbins WendyeDirector | PPurchase | +2.50K | $20.05 | +$50.1K | +62.5%6.50K after | |
| Mar 13, 2023 (view filing) | Mar 7 | 6 daysLate | Ho WilliamChief Medical Officer | SSale | −5.00K | $29.62 | −$148.1K | −16.4%25.5K after | |
| Jan 26, 2023 (view filing) | Jan 24 | 2 days | Ho WilliamChief Medical Officer | SSale | −5.00K | $30.00 | −$150.0K | −14.3%30.1K after |
Top 10 13F holders, Q4 2025
The largest institutional positions in RAPT Therapeutics, Inc. at the end of Q4 2025; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,794,000 | $94.6M | 11.33% | 00.0% | Unchanged |
| TCG Crossover Management, LLC | 2,582,408 | $87.5M | 2.89% | +946,133+57.8% | Added |
| FCPM III Services B.V. | 1,833,333 | $62.1M | 8.14% | +1,489,096+432.6% | Added |
| OrbiMed Advisors LLC | 1,642,891 | $55.6M | 1.14% | +556,273+51.2% | Added |
| RTW Investments, LP | 1,637,165 | $55.5M | 0.56% | +166,666+11.3% | Added |
| Foresite Capital Management VI LLC | 1,562,500 | $52.9M | 16.00% | 00.0% | Unchanged |
| Siren, L.L.C. | 1,375,000 | $46.6M | 1.39% | +794,534+136.9% | Added |
| Vanguard Group Inc | 1,186,791 | $40.2M | 0.00% | +490,603+70.5% | Added |
| Frazier Life Sciences Management, L.P. | 983,333 | $33.3M | 0.89% | +983,333 | New |
| Braidwell LP | 929,694 | $31.5M | 1.01% | +929,694 | New |